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PURPOSE. Vascular endothelial cell growth factor (VEGF) is
strongly induced by oxidative stress in retinal pigment epithe-
lial (RPE) cells, and VEGF-A is a survival factor for various cell
types. This study was conducted to determine whether the
autocrine VEGF signaling pathway in RPE cells is involved in
the mechanism of adaptive response to oxidative stress.
METHODS. ARPE-19 cells were treated with hydrogen peroxide,
and cell death was measured by flow cytometry with annexin
V-fluorescein isothiocyanate. Survival analysis was performed
with pretreatment of VEGF-A–neutralizing antibodies, VEGF
receptor tyrosine kinase inhibitor (SU5416), or VEGF-A recep-
tor-neutralizing antibodies (anti-VEGF-R1 and anti-VEGF-R2).
The expression of VEGF-A, -R1, -R2, and soluble VEGF-R1 was
determined by semiquantitative RT-PCR or Western blot anal-
ysis. Phosphorylation of VEGF-R2 was detected with immuno-
precipitation and immunoblot analysis.
RESULTS. Hydrogen peroxide–induced cell death was pro-
moted by pretreatment with VEGF-A and anti-VEGF-R2–neu-
tralizing antibodies, but not with anti-VEGF-R1–neutralizing
antibody. Phosphorylation of VEGF-R2 in RPE cells was
induced by hydrogen peroxide, and pretreatment with anti-
VEGF-A–neutralizing antibody inhibited phosphorylation.
Phosphorylation of Akt under oxidative stress was abrogated
by pretreatment with neutralizing antibodies against either
VEGF-A or SU5416.
CONCLUSIONS. Autocrine VEGF-A enhanced RPE cell survival
under oxidative stress; the autocrine VEGF-A/VEGF-R2/PI3K/
Akt pathway is involved. Neutralization of VEGF-A signaling, as
in eyes with age-related macular degeneration, may influence
RPE cell survival. (Invest Ophthalmol Vis Sci. 2010;51:
1190–1197) DOI:10.1167/iovs.09-4144
VEGF-A is a potent endothelial cell mitogen, and recentstudies have shown that it acts as an autocrine growth and
survival factor in VEGF-A-producing cells.1–4 Substantial evi-
dence indicates that it is a major mediator of angiogenesis and
vascular leakage in exudative age-related macular degeneration
(AMD).5–9 Inhibition of VEGF-A activity has been a central
theme in many therapies under investigation. Several inhibitors
have been developed and are now used clinically. These in-
clude a VEGF-A–neutralizing oligonucleotide aptamer, a hu-
manized monoclonal antibody Fab fragment (ranibizumab),
and a VEGF-A receptor analog (soluble VEGF receptor 1;
sVEGF-R1). RNA interference (RNAi) has recently emerged as a
potential therapeutic modality, and the first clinical application
of an RNAi—a trial involving siRNA targeting VEGF-A or its
receptor for treatment of AMD by intravitreal injection—is
currently under way.3,9,10 Another method of blocking the
VEGF-A signal is to employ a receptor tyrosine kinase (RTK)
inhibitor to interrupt the signaling. Many RTK inhibitors are
under evaluation for treatment of exudative AMD.6
In normal eyes, VEGF-A receptors are localized to the cho-
riocapillary endothelium opposite the retinal pigment epithe-
lial (RPE) cells. Tonic VEGF-A expression in the RPE may be
trophic for the choriocapillaries and is possibly necessary for
maintenance of the choriocapillaris fenestrae.6,11 However,
VEGF-A levels are significantly higher in patients with neovas-
cular AMD than in healthy control subjects, but the precise
trigger and outcomes of enhanced VEGF-A expression remain
unclear.12,13
VEGF-A expression is increased in the RPE cells of the
macula in patients with AMD, a condition associated with a
high risk of choroidal neovascularization (CNV).7 Also, VEGF-A
is present in fibroblastic cells and transdifferentiated RPE cells
in surgically removed CNV specimens.11,14 The presumed prin-
cipal source of VEGF-A in exudative AMD is the RPE, and
oxidants have been reported to increase the deposition of
oxidized proteins or other oxidized compounds in Bruch’s
membrane, in a process that may involve complement activa-
tion and inflammation, provoking proangiogenic VEGF-A re-
lease from the RPE in patients with exudative AMD.6–8,13,14 In
addition, oxidant compounds, per se, have been shown to
stimulate VEGF-A release from the RPE.13,15 However, the
function of VEGF-A secretion from the RPE under oxidative
stress is teleologically inexplicable.
Cellular damage resulting from oxidative stress in RPE cells
and photoreceptors may play a causative role in aging of the
RPE.5 Oxidative stress-induced RPE cell apoptosis has been
proposed as a major pathophysiological mechanism of
AMD.5,16,17 In particular, RPE cell apoptosis is an important
feature of the advanced form of dry AMD.5,18 Thus, oxidative
stress induces VEGF-A expression from the RPE and also RPE
death, suggesting a role for such stress in both neovascular and
advanced dry AMD.
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Although current treatments that target VEGF-A have dem-
onstrated the best clinical outcomes of all approaches trailed to
date, concern about broad inhibition of VEGF-A activity in
AMD eyes remains.6 VEGF-A is a known survival factor for the
developing and mature retina, stimulating both endothelial and
neural cells.6 Inhibition of VEGF-A has been reported to lead to
geographic atrophy and poor visual outcome in some patients
with neovascular AMD.6 Also, RPE tears and choroidal atrophy
in specimens from patients with treated AMD raise questions
about the long-term safety of anti-VEGF-A treatment.19
It has been suggested that the presence of both VEGF-A
receptors and neuorpilin-1 on transdifferentiated RPE cells and
RPE cell death caused by VEGF-A chimeric toxin signal the
presence of functional VEGF-A receptors on human RPE
cells.20–25 Thus, we were of the view that an investigation of
the relationship between VEGF-A expression and RPE cell
activities, especially under conditions of oxidative stress,
would help to explain the pathogenesis of exudative or dry
AMD.
As VEGF-A is an autocrine survival factor for various cell
types and as it is strongly induced by oxidative stress in RPE
cells, we examined whether the autocrine VEGF-A signaling
pathway is involved in the mechanism of adaptive response to
oxidative stress.7,13,15,26–28
MATERIALS AND METHODS
Chemical Reagents and Cell Culture Medium
Dulbecco’s modified Eagle’s medium (DMEM), F-12 nutrient mixture,
fetal bovine serum (FBS), HEPES buffer, amphotericin B, and gentami-
cin were purchased from Hyclone Laboratories, Inc. (Logan, UT);
VEGF-R1 (Flt-1)-neutralizing antibodies (AF321), VEGF-R2 (Flk-1/KDR)-
neutralizing antibodies (MAB3572), and recombinant human VEGF165
(rhVEGF) from R&D Systems, Inc. (Minneapolis, MN); recombinant
PlGF (placental growth factor, P1588) from Sigma-Aldrich (St. Louis,
MO); anti-VEGF neutralizing antibodies (PC315) and LY294002
(440202) and SU5416 (676487) from Calbiochem (San Diego, CA); and
horseradish peroxidase (HRP)–conjugated secondary antibody from
Dako (Glostrup, Denmark).
Cell Culture
The ARPE-19 cell line was obtained from ATCC (Manassas, VA) and
maintained in DMEM with Ham’s F-12 nutrient medium (DMEM F-12;
Invitrogen-Gibco, Carlsbad, CA). The ARPE-19 cells were used within
10 passages. They were plated in six-well plates at 1.5  105 cells per
well and incubated at 37°C under 5% (vol/vol) CO2 to reach 70%
confluence before exposure to H2O2. They were serum starved before
H2O2 exposure and then treated with H2O2 for 16 hours, to induce
oxidative stress, before they were harvested for cell death analysis.
Flow Cytometric Analysis of Apoptosis
The cells were washed with PBS and incubated in serum-free DMEM in
the presence of H2O2 (200–300 M) for 16 hours. Anti-VEGF-A–
neutralizing antibody or other neutralizing antibodies (anti-VEGF-R1 or
anti-VEGF-R2) were added 2 hours before H2O2 treatment. An annexin
V-fluorescein isothiocyanate (FITC) apoptosis kit (BD Biosciences,
Franklin Lakes, NJ) was used to detect phosphatidylserine externaliza-
tion, as an index of apoptosis. The cells were washed and incubated for
15 minutes at room temperature in the presence of annexin V labeled
with FITC and propidium iodide (PI). In total, 10,000 cells were
excited at 488 nm, and emission was measured at 530 and 584 nm to
assess FITC and PI fluorescence, respectively. The cells were analyzed
with a flow cytometer (flow cytometry; BD Biosciences). The number
of gated cells was plotted on a dot plot with reference to both annexin
V and PI staining.
Semiquantitative RT-PCR
RNA isolation and semiquantitative RT-PCR were performed as described
previously.29 Primer sequences specific for amplification of genes encod-
ing VEGF-A, VEGF-R, sVEGF-R1, membrane-bound (mb)VEGF-R1, and
VEGF-R2 were designed from available human gene sequences (Table 1).
Western Immunoblot Analysis
Adherent cells were washed with ice-cold PBS and lysed with cell lysis
buffer (20 mM HEPES [pH 7.2], 10% glycerol [vol/vol], 10 mM Na3VO4,
50 mM NaF, 1 mM phenylmethylsulfonyl fluoride, 0.1 mM dithiothre-
itol, 1 g/mL leupeptin, 1 g/mL pepstatin, and 1% Triton X-100
[vol/vol]; Sigma-Aldrich) on ice for 30 minutes. Lysates were sonicated
and centrifuged for 10 minutes at 12,000g, and the cell homogenate
fractions were stored at 70°C until used.
Protein concentrations in supernatant fractions were determined
by the Bradford assay. Equal amounts of protein (30 g) were boiled in
Laemmli sample buffer and resolved by 8% (wt/vol) SDS-PAGE. Pro-
teins were transferred to polyvinylidene fluoride (PVDF) membranes
(Immobilon; Millipore, Billerica, MA), probed overnight with primary
antibodies diluted in TBST, and washed three times with TBST. Anti-
VEGF-R2 antibody (2479), anti--actin antibody (4967), anti-phosphor-
Akt (Ser473) antibody (9271), and anti-Akt antibody (9272) were all
obtained from Cell Signaling Technology (Beverly, MA). Anti-VEGF-R1
antibody (ab32152) was the product of Abcam (Cambridge, UK).
Immunoreactive bands were detected with horseradish peroxidase–
conjugated secondary antibody and visualized by enhanced chemilu-
minescence.
TABLE 1. Primer Used for Semiquantitative RT-PCR
Target Gene Primer Sequence
Product Size
(bp)
VEGF Forward 5-ATG GCA GAA GGA GGG CAG CAT-3 255
Reverse 5-TTG GTG AGG TTT GAT CCG CAT CAT-3 255
VEGF-R1 Forward 5-GTAGCTGGCAAGCGCTCTTACCGGCTC-3 316
Reverse 5-GGATTTGTCTGCTGCCCAGTGGGTAGAGA-3 316
mbVEGF-R1 Forward 5-CCA CCT TGG TTG CTG AC-3 587
Reverse 5-TGG AAT TCG TGC TGC TTC CTG GTC C-3 587
sVEGF-R1 Forward 5-CCA GGA ATC ACA CAG G-3 393
Reverse 5-CAA CAA ACA CAG AGA AGG-3 393
VEGF-R2 Forward 5-TCT GGT CTT TTG GTG TTT TG-3 497
Reverse 5-TGG GAT TAC TTT TAC TTC TG-3 497
GAPDH Forward 5-GCC AAG GTC ATC CAT GAC AAC-3 511
Reverse 5-GTC CAC CAC CCT GTT GCT GTA-3 511
sVEGF-R1, soluble VEGF-R1; mbVEGF-R1, membrane-bound VEGF-R1.
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Immunodetection of VEGF-R2 Phosphorylation
After overnight serum starvation, an equal number of ARPE-19 cells
were stimulated with H2O2 (800 M) for 15 minutes in the absence or
presence of anti-VEGF antibody (4 g/mL). rhVEGF (20 ng/mL) was
treated as a positive control. Equal amounts of cell lysate were immu-
noprecipitated with antibody to VEGF-R2 (NEF) immobilized to pro-
tein-A-Sepharose, subjected to SDS-PAGE, immunoblotted with phos-
photyrosine-specific antibody (anti-p-VEGF-R2 [Tyr 996-R], sc-16629-R;
Santa Cruz Biotechnology, Santa Cruz, CA), and reprobed with anti-
serum to VEGF-R2. Protein expression was quantified by densitometry.
Immunocytochemistry
Cells were fixed for 5 minutes in 3.7% (vol/vol) formaldehyde and
permeabilized with 0.5% (vol/vol) Triton X-100 for 8 minutes. Single-
or double-labeled immunofluorescence analysis was performed. In
control experiments, the samples were run without primary antibody
or after addition of an irrelevant IgG, to assess nonspecific binding of
secondary antibody. In all experiments, the samples were incubated
with anti-VEGF-R1 or anti-VEGF-R2 antibody for 2 hours at room tem-
perature, followed by a 1-hour incubation with FITC-conjugated sec-
ondary antibody. Anti-VEGF-R2 antibody (2479; Cell Signaling Technol-
ogy) and anti-VEGF-R1 antibody (AF321; R&D Systems) were used.
After washing with PBS, samples were examined by confocal micros-
copy (TSE SPE Instrument; Leica Microsystems, Wetzlar, Germany).
Enzyme-Linked Immunosorbent Assay
Cells were treated with various concentrations of H2O2 at baseline (0
hours) and at 16 hours. The supernatants were collected, centrifuged
to remove cell debris, and stored at 70°C before ELISA (R&D Sys-
tems), performed according to the manufacturer’s instructions.
VEGF-A levels were adjusted to reflect total protein concentration. The
level of VEGF-A protein was measured in cell-free supernatant using a
human VEGF-A ELISA kit (Quantikine; R&D Systems).
RESULTS
Relevance of Autocrine VEGF-A to RPE Cell
Viability under Oxidative Stress Conditions
As VEGF-A functions as a survival factor for various cell types
and is strongly induced by oxidative stress in RPE cells, we
examined whether survival of RPE cells under oxidative stress
is related to stress-induced VEGF-A synthesis.4,30 Pretreatment
of VEGF-A–neutralizing antibodies to culture medium inhibited
the ability of RPE cells to survive oxidative stress caused by
H2O2 (Figs. 1A, 1B). Furthermore, apoptosis of RPE cells under
oxidative stress conditions was inhibited by concomitant sup-
plementation with rhVEGF (Fig. 1C). This result indicates that
autocrine VEGF-A-mediated survival signals prohibit entry into
the cell death pathway under conditions of oxidative stress.
Expression of VEGF-A, -R2, and -R1 and
Regulation by Oxidative Stress
The concentration of secreted VEGF-A increased in a dose-
dependent manner when H2O2 was added to RPE cells (Fig.
2B). Gene expression analysis indicated that expression of all
VEGF-A, -R1, and -R2 was induced by H2O2 (Fig. 2C). Immu-
nohistocytochemistry showed that both VEGF-R1 and -R2 pro-
tein expression was induced by H2O2 stimulation (Fig. 2D).
Mediation of the Autocrine VEGF-A Cell Survival
Effect by the VEGF-A/VEGF-R2 Axis
Two high-affinity VEGF-A receptors, VEGF-R1 and -R2, are
membrane-spanning receptor tyrosine kinases that bind
FIGURE 1. Autocrine VEGF-A pro-
tected against H2O2-induced cell
death in ARPE-19 cells. (A) Immortal-
ized ARPE-19 cells were cultured
with 10% fetal bovine serum and
DMEM:F12 medium. When the cells
were 70% confluent, anti-VEGF anti-
body was treated 2 hours before
treatment with 300 M of H2O2. Af-
ter 16 hours of H2O2 treatment, pho-
tographs were taken by inverted mi-
croscopy. Bar, 100 m. (B) ARPE-19
cells were incubated with 200 M
H2O2 for 16 hours, and the cells were
next analyzed by using annexin V-
fluorescein isothiocyanate and PI
staining. Each panel shows a typical
flow cytometric histogram of 10,000
cells/sample from a representative
experiment. LL, viable and undam-
aged cells (annexin V, PI); RL,
cells undergoing early apoptosis (an-
nexin V, PI); RU, necrotic or late
apoptotic cells (annexin V, PI).
(C) ARPE-19 cells were incubated
with 200 M H2O2 for 16 hours. Cell
survival was then analyzed by flow
cytometry. Each bar shows the
mean  SD of results in 9 to 12 wells
in three independent experiments.
*P  0.001 compared with control.
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VEGF-A, but their effects on VEGF-A signaling are very dif-
ferent. VEGF-A signaling through VEGF-R2 produces several
cellular responses, including a strong mitogenic signal and a
survival signal for endothelial cells and many other cell
types.4,30 However, VEGF-A binding to VEGF-R1 does not
produce a strong mitogenic signal in endothelial cells. We
found that of the two high-affinity VEGF-A receptors,
VEGF-R1 and -R2, only VEGF-R2 mediated the cell survival
signals. H2O2-induced cell death was promoted by pretreat-
ment with anti-VEGF-R2–neutralizing antibody, but not with
the use of anti-VEGF-R1–neutralizing antibody (Figs. 3A, 3B).
Unlike the situation with VEGF-A, which is a ligand for both
VEGF-R1 and -R2, PlGF binds only to VEGF-R1, not to VEGF-
R2. In a previous result, H2O2-induced cell death was inhib-
ited by supplementation with rhVEGF, but PlGF did not
prevent the cell death caused by anti-VEGF-A–neutralizing
antibody (Fig. 3D).
The phosphorylation levels of VEGF-R2 were measured by
immunoblot analysis for phosphotyrosine after immunopre-
cipitation of VEGF-R2. When stimulated with H2O2, the phos-
phorylated VEGF-R2/total VEGF-R2 ratio was increased by ap-
proximately 190% but did not increase on pretreatment with
anti-VEGF-A antibody (Fig. 4B). Phosphorylation of VEGF-R2 in
RPE cells was induced by oxidative stress; however, pretreat-
ment with anti-VEGF-A–neutralizing antibody inhibited phos-
phorylation. These results are consistent with our earlier data
indicating that RPE cells can survive oxidative stress with the
assistance of autocrine VEGF-A signaling.
The Autocrine VEGF-A Axis Influence on the
Phosphorylation of the Akt Signal Protein
In RPE cells, it has been reported that the PI3k-Akt pathway
stimulated by H2O2 is involved in protection against oxidant-
induced cell death in both normal conditions and disease states
such as AMD.12 The PI3K/Akt pathway has been proposed to
be activated in a VEGF-R2-dependent fashion in other cell
types.31,32 Survival signaling from VEGF-R2 in endothelial cells
also has been reported to involve the PI3K/Akt pathway.31 We
thus explored whether blocking of the autocrine VEGF-A loop
influences Akt phosphorylation.
RPE cells were cultured with 300 M H2O2 in the presence
or absence of anti-VEGF-A–neutralizing antibodies, and ty-
rosine phosphorylation of Akt was measured in the cell lysates.
H2O2-induced phosphorylation of Akt was abrogated by pre-
treatment with A-neutralizing antibody against VEGF-A or
SU5416 (Figs. 5A, 5C). The data thus suggest that the VEGF-A/
VEGF-R2/PI3K/Akt pathway activation is involved in the resis-
tance to cell death caused by H2O2 stress.
Soluble VEGF-R1 Regulation of the Autocrine
VEGF-A Signal
It has been reported that sVEGF-R1 acts as an effective signal-
ing modulator by regulating the availability of free VEGF-A in
the microenvironment.33,34 The action of VEGF-A is depen-
dent, not only on the concentration of free VEGF-A and the
expression level of VEGF-R2 on the cell surface, but also on the
concentration of the negative regulator (e.g., sVEGF-R1). Dur-
FIGURE 2. Expression of VEGF-A
and VEGF receptors by H2O2 in
ARPE-19 cells. (A) After 1 hour of
H2O2 treatment, VEGF-A mRNA ex-
pression in APRE-19 cells was deter-
mined in a dose-dependent manner.
(B) VEGF-A excretion into the medium
wasmeasured by ELISA. After 16 hours
of treatment with H2O2, supernatant
was collected and analyzed by ELISA.
Data are expressed as the mean  SD
of the results in three independent ex-
periments. (C) VEGF-R1 and -R2 mRNA
expression was determined after H2O2
treatment. Each mRNA level was mea-
sured 1 hour after inoculation of various
concentrations of H2O2. (D) Expression
pattern of VEGF-R1 and -R2 was investi-
gated by immunocytochemical staining.
The cellswere exposed to 300MH2O2
for 6 hours, fixed with formaldehyde,
and incubatedwith anti-VEGF-R1 or anti-
VEGF-R2 antibody for 2 hours at room
temperature, followed by a 1-hour incu-
bation with FITC-conjugated secondary
antibody. The images were obtained
with a confocal microscope. Green:
VEGF-R1 or R2; blue: DAPI. Bar, 25 m.
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ing oxidative stress, transcription of both VEGF-A and
sVEGF-R1 was concomitantly induced (Fig. 6A). The transcrip-
tion level of sVEGF-R1, however, appeared to be regulated by
the environmental free VEGF-A concentration. When the free
available VEGF-A level was reduced, the transcription of
sVEGF-R1 decreased, but when VEGF-A was present at high
concentrations, the sVEGF-R1 level rose (Fig. 6B).
Influence of Bevacizumab on Survival of RPE
Cells under Oxidative Stress
Intravitreal injection of a humanized monoclonal antibody
against VEGF-A (bevacizumab, Avastin; Genentech/Roche,
South San Francisco, CA) currently finds wide clinical applica-
tion. Addition of a high concentration (2.5 mg/mL) bevaci-
zumab to the culture medium did not affect the survival of
either control RPE cells or cells under a low level of oxidative
stress (150 M H2O2; Fig. 7). However, under higher stress
levels (200 or 300 M H2O2), pretreatment with bevacizumab
induced a significantly higher level of cell death (Fig. 7).
DISCUSSION
The presence of functional VEGF-A receptors on RPE cells,
transmitting signals similar to those mediated by receptors on
endothelial cells, suggests that targeting of these receptor ty-
rosine kinases, either through the use of neutralizing antibody
or kinase inhibitors, has clinical potential, permitting modula-
tion of RPE survival or proliferation through autocrine VEGF-A
signaling.4,27 The main therapeutic mechanisms of anti-VEGF-A
agents are based on antileakage effects and regression or mat-
uration of CNV. Even with such an effect, progressive fibrosis
and residual inflammatory processes are postulated to cause
damage to RPE cells and photoreceptors.6 RPE cell survival is
crucial for maintaining the normal function of the overlying
FIGURE 3. The VEGF/VEGF-R2 axis,
but not that of VEGF/VEGF-R1, medi-
ated the VEGF cell survival effect in
ARPE-19 cells. Each antibody was
added 2 hours before treatment with
200 M H2O2 for 16 hours. Cell
death was analyzed by flow cytom-
etry of cells tagged with FITC-labeled
annexin V and PI. H2O2-induced cell
death was aggravated by pretreat-
ment with anti-VEGF-R2 (A) but not
by pretreatment with anti-VEGF-R1
antibody (B). (C) Cell survival analy-
sis using flow cytometry showed that
ARPE-19 cell survival was reduced by
pretreatment with a VEGF-R2-spe-
cific PTK inhibitor (SU5416) in the
presence of 300 M H2O2 for 16
hours. (D) H2O2-induced cell death
was promoted by pretreatment with
anti-VEGF antibody, but the cells
were rescued if rh-VEGF165 was
added. However, pretreatment with
rh-PlGF, a substrate of VEGF-R1 only
(thus not of VEGF-R2), did not pre-
vent the cell death caused by pre-
treatment with anti-VEGF antibody.
FIGURE 4. Determination of phos-
phorylated VEGF-R2 in APRE-19 by
H2O2 treatment. (A) For positive con-
trol, phosphorylation of VEGF-R2 in
ARPE-19 cells was determined by
treating with rhVEGF. A nearly con-
fluent monolayer of ARPE-19 cells
was treated with 20 ng/mL of
VEGF-A in serum-free medium for 24
hours. Then the cells were collected
and lysed by protein lysis buffer. Im-
munoprecipitation was performed
400 g of cell lysate with using 1 g
of anti-VEGF-R2 and 40 L of protein
G Sepharose. Immunoblot analysis
was performed with phosphor-
VEGF-R2 antibody. (B) Phosphor-
VEGF-R2 expression under oxidative
stress in the absence and presence of anti-VEGF antibody was determined by immunoprecipitation for VEGF-R2. The cells were treated with 800
M of H2O2 for 15 minutes and lysed with cell lysis buffer. Immunoprecipitation and immunoblot analyses were then performed. There were
differences in loading of VEGF-R2, the phosphor-VEGF-R2/total VEGF-R2 levels, as follows: lane 1: 100%; lane 2: 190%; lane 3: 100%; lane 4: 90%.
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neurosensory retina and the underlying choriocapillaries. In
the CNV regression area, RPE cells also proliferate and wrap
around new vessels, thus forming a novel outer blood–retinal
barrier (BRB).8,19
Our results imply that neutralization of VEGF-A signaling
with an anti-VEGF-A agent in AMD eyes influences RPE cell
survival, which is essential for visual recovery and reduction of
AMD recurrence. It may therefore be important to modulate
the extent of VEGF-A blockade, or to specifically and selec-
tively inhibit only one or a few of the angiogenic actions of
VEGF-A, when considering VEGF-A inhibition as a treatment
strategy.
In RPE cells, Akt signaling has been postulated to compen-
sate for oxidative injury and to prevent apoptotic cell death.12
Blocking PI3K-Akt significantly enhances H2O2-induced RPE
cell apoptosis and cell death.12 We found that autocrine
VEGF-A signaling affected the Akt signaling pathway, which
may be used by RPE cells to survive under conditions of
oxidative stress.12
In pathologic specimens of CNV, RPE cells show excessive
proliferation and resultant subretinal scarring.8 It is not known
whether this effect is attributable to loss of RPE cell function
under chronic oxidative stress or to perturbation of RPE func-
tion by underlying AMD pathogenesis.8 Our study was per-
formed on low-passage, low-density cultures of ARPE-19 cells
that showed relatively undifferentiated growth characteristics
and were quite sensitive to oxidative stress.35 When disease
(e.g., AMD) is present, RPE cells adjacent to CNV undergo
transformation and proliferation. Thus, RPE cells under our
experimental conditions may simulate those in an in vivo
pathologic lesion, compared with long-term culture of RPE
cells. In vivo, RPE cells are always exposed to oxidative stress
from lipid peroxides, and anti-VEGF-A agents are currently
clinically used to treat RPE disease, but not when the RPE is
normal. Another important indication for anti-VEGF-A treat-
ment is diabetic retinopathy, where RPE cells are exposed to a
pathologic level of oxidative stress in vivo.
We found that RPE cells secreted not only VEGF-A but also
sVEGF-R1, and production of sVEGF-R1 appeared to be regu-
lated by the environmental level of VEGF-A. sVEGF-R1 is a
naturally occurring protein antagonist of VEGF-A, formed by
alternative splicing of the pre-mRNA for the full-length recep-
tor.33,34 sVEGF-R1 negatively modulates developmental blood
vessel formation by inhibition of signaling through VEGF-R2.
We found that sVEGF-R1 may play a regulatory role in RPE
cells. In vivo, fine-tuning of the effective VEGF-A level in the
outer retina is very important, because aberrant angiogenesis
in the retina may cause severe tissue damage. Thus, we hy-
pothesize that the effective VEGF-A level in RPE cells is tightly
regulated by synchronous production of sVEGF-R1, the se-
creted extracellular domain of VEGF-R1.
FIGURE 5. Akt phosphorylation by
the autocrine VEGF-A and its recep-
tor activation pathway. (A) An immu-
noblot probed with antibody to
phosphor-Akt (p-Akt) (Ser473) and
antibody to total-Akt (t-Akt), a con-
trol for gel loading. ARPE-19 cells
were treated with 300 M H2O2 for
various times, with or without pre-
treatment with anti-VEGF antibody.
The immunoblot was probed with
antibody to p-Akt (Ser473) and anti-
body to t-Akt 15 minutes after treat-
ment with H2O2. (B) Pretreatment
with a PI3K-specific inhibitor
(LY294002), acting upstream of Akt,
blocked phosphorylation of Akt. (C)
Pretreatment with an VEGF-R2-spe-
cific RTK inhibitor (SU5416) blocked
phosphorylation of Akt.
FIGURE 6. Expression of soluble VEGF-R1 by autocrine VEGF signaling under conditions of H2O2 stress.
Soluble VEGF-R1 (sVEGF-R1) acted as an effective signaling modulator by regulating the availability of free
VEGF in the microenvironment with VEGF-R2 then functioning as the primary receptor for VEGF. (A)
Gene expression of sVEGF-R1, mbVEGF-R1,and VEGF-R2, after 1hour of H2O2 stress. (B) Gene expression
of sVEGF-R1 and mbVEGF-R1 after treatment with anti-VEGF antibody or rhVEGF.
IOVS, February 2010, Vol. 51, No. 2 Autocrine Survival Signal of VEGF in RPE 1195
Bevacizumab is a full-length, recombinant, humanized
monoclonal antibody binding to all VEGF-A isoforms. Because
of this general binding pattern for VEGF-A, bevacizumab is
presumed to be as effective as ranibizumab in the treatment of
intraocular neovascularization. Experimental investigations in
rats, rabbits, and primates showed that intravitreal bevaci-
zumab at a different concentration did not cause any functional
and morphologic retinal toxicity.36–38 In vitro cellular assays
examining exposure to bevacizumab have shown little toxic
effect on ganglion cells, neuroretinal cells, RPE cells, choroidal
endothelial cells, and corneal epithelial cells.39–43 However, in
a recent rabbit eye study, the TUNEL method showed that
increasing the dosage with intravitreal bevacizumab can cause
nuclear DNA fragmentation in the outer retinal layers.44 Also,
in a mouse model, systemic neutralization of VEGF led to
significant cell death in the inner and outer nuclear cell layer
and loss of visual function.45 As shown in our study, high doses
of bevacizumab significantly induced RPE cell death under
conditions of higher oxidative stress, which may be attribut-
able to blocking of the VEGF-A autocrine survival signal (Fig.
7). However, we used a greater dose of bevacizumab than is
used clinically, and RPE cell death was induced only at higher
levels of oxidative stress. Further clinical evaluation of the
long-term safety of bevacizumab is needed.
The present study provides evidence that VEGF-A assists in
RPE cell survival when cells are exposed to oxidative stress and
that the autocrine VEGF-A/VEGF-R2/PI3K/Akt pathway is in-
volved. Our results imply that neutralization of VEGF-A signal-
ing, with an anti-VEGF-A agent, in AMD eyes, influences RPE
cell survival. A high level of VEGF-A secreted from RPE cells
under oxidative stress conditions may participate in the patho-
genesis of exudative AMD (by stimulating CNV); however,
VEGF-A may have a beneficial effect in assisting RPE cell resis-
tance against oxidative stress. Bevacizumab, now extensively
used in the ophthalmic field, may also affect RPE cell survival
under conditions of high oxidative stress. Thus, the extent or
specificity of VEGF-A blockade, and the level of oxidative
stress, may affect treatment outcomes (survival of RPE cells,
restoration of outer BRB, or geographic atrophy) when anti-
VEGF-A treatment is used in patients with neovascular AMD.
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